Literature DB >> 19302689

Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study.

Jeronimo Jurado1, Juan Ybarra, Pascual Solanas, Jacint Caula, Ignasi Gich, Jose M Pou, June Hart Romeo.   

Abstract

PURPOSE: The purpose of the study was to evaluate the prevalence of cardiovascular disease (CVD), cardiovascular risk factors (CVRFs), and their control in patients with type 2 diabetes mellitus (T2DM) at primary care settings from the North Catalonia Diabetes Study (NCDS). DATA SOURCES: In this multicentre cross-sectional descriptive study, data were collected from a random sample of 307 patients with T2DM. The prevalence of CVD, CVRF, metabolic syndrome (MS), coronary heart disease (CHD) risk at 10 years (Framingham Point Scores), and CVRF control was evaluated. MS and lipid profiles were established according to Adult Treatment Panel III criteria.
CONCLUSIONS: CVD prevalence was 22.0% (CHD: 18.9% and peripheral ischemia: 4.5%) and more frequent in men. The prevalence of selected CVRF was: hypertension: 74.5%; dyslipidemia: 77.7%; smoking: 14.9%; obesity 44.9%, and familial CVD: 38.4%. Three or more CVRFs, including T2DM, were observed in 91.3%. MS prevalence was 68.7%. Framingham score was 10.0%, higher in men than in women. CVD prevalence was related to: age, number of CVRFs, duration of diabetes, familial history of CVD, waist circumference, hypertension, lipid profile, kidney disease, and Framingham score, but not to MS by itself. Correct lipid profiles and blood pressure were only observed in 18.9% and 24.0%, respectively, whereas platelet aggregation inhibitors were only recorded in 16.1% of the patient cohort. MS presence was not an independent risk factor of CVD in our study. IMPLICATIONS FOR PRACTICE: The high prevalence of CVD and an inadequate control of CVRF, which were apparent in the NCDS population, would suggest that advanced practice nurses should consider incorporating specific cardiovascular assessment in their routine care of persons with T2DM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302689     DOI: 10.1111/j.1745-7599.2008.00377.x

Source DB:  PubMed          Journal:  J Am Acad Nurse Pract        ISSN: 1041-2972


  13 in total

Review 1.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

2.  Thoracic periaortic adipose tissue in relation to cardiovascular risk in type 2 diabetes mellitus.

Authors:  Ömer Akyürek; Duran Efe; Zeynettin Kaya
Journal:  Wien Klin Wochenschr       Date:  2014-10-22       Impact factor: 1.704

3.  Comparative study of clinical characteristics between Chinese Han and German Caucasian patients with coronary heart disease.

Authors:  Yali Zheng; Wenfei Ma; Yan Zeng; Jiani Liu; Shan Ye; Shaohua Chen; Ling Lan; Raimund Erbel; Qigong Liu
Journal:  Clin Res Cardiol       Date:  2009-09-18       Impact factor: 5.460

4.  Atherosclerotic cardiovascular disease among patients with type 2 diabetes in Basrah.

Authors:  Abbas Ali Mansour; Narjis Ah Ajeel
Journal:  World J Diabetes       Date:  2013-06-15

5.  [Withdrawal of a specialised diabetes education program in primary care: long term impact on the metabolic control outcomes].

Authors:  Jerónimo Jurado Campos; Jacint A Caula Ros; Josep M Hernández Anguera; Dolors Juvinyà Canal; José M Pou Torelló
Journal:  Aten Primaria       Date:  2009-05-29       Impact factor: 1.137

Review 6.  Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review.

Authors:  Esther Artime; Irene Romera; Silvia Díaz-Cerezo; Elías Delgado
Journal:  Diabetes Ther       Date:  2021-05-03       Impact factor: 2.945

7.  Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: the ECOBIM study.

Authors:  Tatiana Dilla; Amparo Valladares; Claudia Nicolay; Javier Salvador; Jesús Reviriego; María Costi
Journal:  Appl Health Econ Health Policy       Date:  2012-11-01       Impact factor: 2.561

8.  Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.

Authors:  Michael J Davies; Katherine Merton; Ujjwala Vijapurkar; Jacqueline Yee; Rong Qiu
Journal:  Cardiovasc Diabetol       Date:  2017-03-21       Impact factor: 9.951

9.  Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.

Authors:  Thomas R Einarson; Annabel Acs; Craig Ludwig; Ulrik H Panton
Journal:  Cardiovasc Diabetol       Date:  2018-06-08       Impact factor: 9.951

Review 10.  Why primary obesity is a disease?

Authors:  Antonino De Lorenzo; Santo Gratteri; Paola Gualtieri; Andrea Cammarano; Pierfrancesco Bertucci; Laura Di Renzo
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.